NCT04471038View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 29, 2020

Primary Completion Date

April 19, 2021

Study Completion Date

April 19, 2021

Conditions
Influenza Type AInfluenza Type BInfluenza
Interventions
BIOLOGICAL

SAB-176

Anti-Influenza Human Immunoglobulin Intravenous (Tc bovine derived)

OTHER

Normal Saline

Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm

Trial Locations (1)

78744

PPD, Phase 1 Clinic, Austin

All Listed Sponsors
lead

SAb Biotherapeutics, Inc.

INDUSTRY

NCT04471038 - Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants | Biotech Hunter | Biotech Hunter